Resources Repository
-
EditorialPublication 2020Waiting for Certainty on COVID-19 Antibody Tests — At What Cost?
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation …
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation policy to reduce COVID-19 transmission. For example: Could we screen for serologic antibodies as a proxy for possible immunity and identify people who could return to the workplace with less severe mitigation measures? The authors acknowledge the uncertainties raised by many policy actors, including the WHO, such as, "Do antibodies confer immunity and, if so, for how long? How accurate is…
Test Performance | Technology Assessment | Global | Policy/Regulation | Probability/Bayes | Infectious Diseases | Health Systems | Government/Law | Health/Medicine | North America -
ReportPublication 2017DCP3: Improving Health and Reducing Poverty
This report from the World Bank is the ninth and final volume of the Disease …
This report from the World Bank is the ninth and final volume of the Disease Control Priorities, Third Edition (DCP3) series. It provides an overview of the findings and methods explored in the first eight volumes, placing them within a framework that identifies an efficient pathway toward essential universal health coverage through the implementation of 21 essential packages that include health interventions and fiscal and intersectoral policies. The Disease Control Priorities Network (DCP) promotes and…
Evidence Synthesis | Global | Policy/Regulation | Social Determinants | Costing Methods | Health Outcomes | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Infectious Diseases | Maternal/Reproductive Health | Child/Nutrition | Chronic Disease/Risk | Mental Health | Injuries/Accidents | Health Systems | Global Governance | Economics/Finance | Government/Law | Health/Medicine | Science/Technology -
ReportPublication 2018Understanding the Economics of Microbial Threats: Proceedings of a Workshop
This report follows a June 2018, Forum on Microbial Threats that was held at the …
This report follows a June 2018, Forum on Microbial Threats that was held at the National Academies of Sciences, Engineering, and Medicine. This was a 1.5-day public workshop with the goal being an assessment of the current understanding of the interaction of infectious disease threats and economic activity in order to suggest future areas of research. This workshop built on prior work of the Forum and aimed to build more mutual understanding between those in…
Evidence Synthesis | Technology Assessment | Global | Policy/Regulation | Health Outcomes | Infectious Diseases | Global Governance | Clinical Care | Business/Industry | Economics/Finance | Health/Medicine -
ReviewPublication 2016Economic Dimensions of Noncommunicable Diseases in Latin America and the Caribbean
This companion volume to Disease Control Priorities, Third Edition (DCP3), explores the impact of noncommunicable diseases …
This companion volume to Disease Control Priorities, Third Edition (DCP3), explores the impact of noncommunicable diseases (NCDs) on development and economic growth in the countries of Latin America and the Caribbean (LAC). This collection of manuscripts examines the complex interplay among NCDs, health expenditures and financial investments in health, poverty, and inequities, using up-to-date information and evidence from the LAC region. There is compelling proof that NCDs are a major and growing problem for low- and…
Technology Assessment | Latin America & Caribbean | Policy/Regulation | Social Determinants | Priority Setting/Ethics | Costing Methods | Cost-Effectiveness Analysis | Child/Nutrition | Chronic Disease/Risk | Mental Health | Health Systems | Economics/Finance | Food/Agriculture | Health/Medicine -
ReviewPublication 2023Handbook of Vaccine Health Economics
The open-access book, "Handbook of Applied Health Economics in Vaccines," looks at the complexities of …
The open-access book, "Handbook of Applied Health Economics in Vaccines," looks at the complexities of vaccine discovery, financing, and distribution. It highlights the inadequacy of standard economic models for vaccines. The book explores alternative principles challenging market-based approaches and equips readers with tools for assessing costs and benefits through practical exercises. It serves as a comprehensive resource for decision-making in vaccine development and distribution and emphasizes the importance of considering broader perspectives beyond economic efficiency.…
Evidence Synthesis | Global | Policy/Regulation | Costing Methods | Health Outcomes | Decision Analysis | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Health/Medicine | Graduate | Doctoral | Professional -
ArticlePublication 2022Conceptualizing Monetary Benchmarks for Health Investments toward Poverty Reduction
Public spending can improve population well-being, for example, by averting or reducing poverty. This article …
Public spending can improve population well-being, for example, by averting or reducing poverty. This article aims to conceptualize monetary benchmarks for health sector investments oriented towards poverty alleviation in low- and lower-middle-income countries. Priority setting in low- and lower-middle-income countries could be informed by health-sector PRBs (poverty reduction benchmarks), in addition to burden of disease and cost-effectiveness considerations. The computed PRBs, expressed in dollars per poverty case averted, can possibly be viewed in a manner…
Evidence Synthesis | Global | Social Determinants | Priority Setting/Ethics | Health Systems | Economics/Finance | Health/Medicine -
ReportPublication 2018Human Development Indices and Indicators: 2018 Statistical Update
This report from the United Nations Development Programme (UNDP) presents the latest reporting on key …
This report from the United Nations Development Programme (UNDP) presents the latest reporting on key human development indices and statistics. It provides a snapshot of current conditions and long-term trends and culminates with a comprehensive statistical annex of human development composite indices and indicators across several dimensions (e.g., health, education, poverty, and inequality). The publication emphasizes that while people are living longer and are more educated than ever before, this may not automatically translate to…
Evidence Synthesis | Global | Social Determinants | Health Outcomes | Health Systems | Climate/Environment | Economics/Finance | Education/Labor | Health/Medicine | Science/Technology -
ReportPublication 2019Human Development Report 2019: Beyond Income, Beyond Averages, Beyond Today
This 2019 Human Development Report, published annually by the United Nations Development Programme (UNDP), explores …
This 2019 Human Development Report, published annually by the United Nations Development Programme (UNDP), explores the contemporary nature of inequalities in human development. Additional resources include digital versions and translations of the Report and the overview in more than 10 languages, an interactive web version of the Report, a set of background papers and think pieces commissioned for the Report, interactive data visualizations and databases of human development indicators, full explanations of the sources and…
Evidence Synthesis | Global | Social Determinants | Health Outcomes | Health Systems | Climate/Environment | Economics/Finance | Education/Labor | Health/Medicine | Science/Technology -
ArticlePublication 2018Comparing Cost-per-QALYs Gained to Cost-per-DALYs Averted
The authors examined 6,438 cost-per-QALY and 543 cost-per-DALY studies published through 2016 using two databases, …
The authors examined 6,438 cost-per-QALY and 543 cost-per-DALY studies published through 2016 using two databases, the Tufts Medical Center CEA Registry (cost-per-QALY gained studies), and the Global Cost-Effectiveness Analysis (GHCEA) Registry (cost-per-DALY averted studies). Study characteristics that were analyzed included intervention type, sponsor, country, primary disease, and number of CEAs versus disease burden estimates for major conditions. The authors report that cost-per-QALY studies were most often about pharmaceuticals or interventions in high-income countries while cost-per-DALY…
Evidence Synthesis | Global | Policy/Regulation | Cost-Effectiveness Analysis | Health/Medicine